N itric oxide ( ⅐ NO, nitrogen monoxide) is recognized for maintaining vascular tone by stimulating cGMP synthesis. Independent of this activation of soluble guanylate cyclase (sGC), other mechanisms can underlie the multifaceted roles of ⅐ NO as a mediator of vascular function and inflammatory responses. ⅐ NO and its metabolites are capable of stimulating and inhibiting lipid oxidation, modulating enzymatically catalyzed lipid oxidation, complexing with lipid-reactive metals, and altering proinflammatory gene expression. Through these mechanisms, ⅐ NO can potentially regulate lipid oxidation and eicosanoid synthesis, thereby impacting on the genesis and progression of inflammatory vascular diseases. The influence of ⅐ NO is a function of the local cellular milieu of reactive oxygen species, which biological antioxidants are present, the relative concentrations of reactants and substrates, and the relative rate constants of possible reactions.
⅐ NO Biosynthesis and Physical-Chemical Properties
⅐ NO, a free radical signal-transducing agent, is synthesized endogenously by nitric oxide synthase (NOS) isoenzymes that oxidizes L-arginine to L-citrulline and are present in a variety of cell types, including vascular endothelial cells, smooth muscle cells, platelets, neuronal cells, macrophages, and neutrophils. 1 There are constitutive NOS (neuronal NOS [type I] and endothelial NOS ([type III]) isoforms as well as an inducible NOS (iNOS, type II). Unlike typical signaling molecules, ⅐ NO is freely diffusible, reacts with a diverse array of intracellular targets, and manifests biological effects that are dependent on the local chemical environment. 2 ⅐ NO is a small lipophilic molecule with a biological half-life of several seconds; thus, it can easily diffuse into and across plasma membranes and lipoproteins. As a free radical, ⅐ NO readily reacts with other radical species (eg, superoxide [O 2 ⅐Ϫ ], lipid alkoxyl [LO ⅐ ], and peroxyl [LOO ⅐ ] radicals) and the metal centers of metalloproteins. The most well-characterized metal-binding action of ⅐ NO is its capacity to bind to the heme iron of sGC and stimulate the production of cGMP. 3 This activates cGMP-dependent kinases and membrane ion channels, decreases intracellular calcium levels, and allows smooth muscle to relax. 4 Thus, ⅐ NO has been identified as an endothelium-derived relaxing factor and as a central modulator of blood pressure. 5 Stimulation of sGC by ⅐ NO also inhibits platelet aggregation and vessel wall adhesion of platelets.
Oxidative Reactions of ⅐ NO
There are also critical guanylate cyclase-independent reactions of ⅐ NO. The major biological end products of ⅐ NO metabolism are nitrite (NO 2 Ϫ ) and nitrate (NO 3 Ϫ ), both of which are excreted in the urine. During metabolism to NO 2 Ϫ /NO 3 Ϫ , ⅐ NO can undergo a series of reactions that generate reactive nitrogen species having a variety of oxidative states (Table 1) . Aerobically, ⅐ NO reacts with oxygen to form nitrogen dioxide ( ⅐ NO 2 ; see Equation 1). Because ⅐ NO and oxygen can concentrate 2-to 8-fold in membranes, the reaction between ⅐ NO and oxygen can be accelerated up to 300-fold in a hydrophobic environment, such as the core of LDL or membranes, in contrast to an aqueous environment. 6 (1) 23 Trans-arachidonic acids (arachidonic acid having 1 trans double bond and 3 cis double bonds) are also generated after exposure of all cis-arachidonic acid to ⅐ NO 2 . These trans-arachidonic acids are produced by platelets exposed to ⅐ NO 2 and can be found in human plasma and urine. 14-Nitro-15-hydroxyeicosatrienoic acid is also detected after ⅐ NO 2 reaction with arachidonic acid. 24 Thus, ⅐ NO can modify phospholipids and fatty acids to potentially bioactive products, by forming nitrated lipid derivatives and altering cis/trans conformations.
⅐ NO-mediated inhibition of lipid peroxidation consumes 2 molecules of ⅐ NO per ROO ⅐ . 25 With oxidizing linoleic acid, ⅐ NO first reacts with LOO ⅐ , where kϭ2ϫ10 25 to form an unstable organic peroxynitrite (LOONO) intermediate that quickly decomposes (kϭ0.1 to 0.3 s Ϫ1 20 ) to generate an alkoxyl radical (RO ⅐ ) and ⅐ NO 2 as a caged radical pair (RO ⅐ -⅐ NO 2 ). Then, a second molecule of ⅐ NO can react with RO ⅐ to form an alkyl nitrite, RNO 2 , where kϭ2ϫ10
. 26 Other reactions and rearrangements are also possible, yielding derivatives such as epoxyallylic radicals and aldehydes. 23, 25 ⅐
NO Can Modulate Lipid Oxidation by Reacting With Cellular Pro-Oxidants and Antioxidants
When metals capable of initiating lipid oxidation become complexed with ⅐ NO to yield metal-nitrosyl derivatives, lipids can be protected from oxidation. Both the ferrous (Fe 2ϩ ) and ferric (Fe 3ϩ ) forms of heme proteins can quickly react with ⅐ NO, where kϭ10 7 (mol/L) Ϫ1 ⅐ s Ϫ1 and kϭ10 2 to 10 7 (mol/L) Ϫ1 ⅐ s Ϫ1 for ferrous and ferric forms, respectively, 27 thus preventing the formation of oxidant ⅐ NO metabolites as well as reducing the redox state of the metal. For example, myoglobin and hemoglobin oxoferryl species ( ⅐ Mb-Fe IV ϭO/ ⅐ Hb-Fe IV ϭO) are reduced to their respective ferric (met) forms on reaction with ⅐ NO, protecting against oxidative damage. 28 Additionally, methemoglobin binds ⅐ NO to form a nitrosyl-hemoglobin ( ⅐ NO-Hb) intermediate that loses its ability to oxidize linoleic acid and produce conjugated dienes as well as the ability to co-oxidize substrates such as ␤-carotene. 29 In general, when ⅐ NO complexes with metalloproteins, lipids are protected from further oxidation by metals and oxidant metabolites of ⅐ NO. However, the relative extent of this reaction in oxidizing membranes and lipoproteins is unclear, because the rate of ⅐ NO reaction with oxidationpropagating species such as LOO ⅐ is 10
In contrast, oxidant metabolites of ⅐ NO can deplete enzymatic and low molecular weight cellular antioxidants, reducing the likelihood of the termination of free radical lipid propagation reactions. Glutathione peroxidase (GPx), an enzymatic antioxidant, decreases lipid oxidation by reducing hydroperoxides to alcohols. The reactive nitrogen speciesproducing compounds-S-nitroso-N-acetyl-D,L-penicillamine (SNAP), 3-morpholinosydnonimine-N-ethylcarbamide, and synthetic ONOO Ϫ -have all been shown to inhibit GPx. 31, 32 The inactivation induced by the ⅐ NO donor SNAP involves a multiple-step mechanism, whereas the inactivation by the more powerful oxidant, ONOO Ϫ , is an irreversible reaction. This occurs because ONOO Ϫ yields more nitrosonium ion (NO ϩ ) than does SNAP, with NO ϩ responsible for oxidizing the active site selenocysteine residue (Sec 45 ) of GPx to a selenenyl sulfide (Se-S) having a free thiol, thereby inactivating the enzyme. 32 Once GPx is inhibited, it can no longer scavenge peroxides and terminate propagating lipid oxidation reactions; therefore, lipid oxidation can be expected to increase. In addition to inhibiting GPx, ONOO Ϫ also oxidizes low molecular weight plasma antioxidants, including the GPx-reducing cofactor glutathione. 33 When ONOO Ϫ is added to plasma, ascorbic acid, uric acid, and plasma thiols are depleted, and lipid hydroperoxide derivatives increase. Ascorbic acid is the plasma antioxidant most significantly affected by ONOO Ϫ . 34 By impairing cellular defenses against lipid oxidation through the depletion of antioxidants and inhibition of GPx, oxidant reactions can greatly increase the rate of lipid peroxidation and lipoprotein modification.
⅐ NO Inhibits LDL Oxidation by Terminating Radical-Mediated Chain Propagation Reactions
Just as ⅐ NO inhibits the oxidation of purified lipids, it also inhibits the oxidation of LDL by scavenging LOO ⅐ via chain-terminating interactions of ⅐ NO and other reactive nitrogen species with LOO ⅐ , yielding oxidized and nitrogencontaining lipid products (A.B. et al, unpublished data, 1999). Pure ⅐ NO, along with the ⅐ NO sources sodium nitroprusside and SNAP, inhibit LDL oxidation initiated by Cu 2ϩ or 2Ј,2Ј-azo-bis(2-amidinopropane)hydrochloride. 35 ⅐ NO can also inhibit LDL oxidation in cellular systems. Murine peritoneal macrophages, having iNOS activity stimulated by interferon-␥ and lipopolysaccharide, are less capable of oxidizing LDL than are unstimulated macrophages. 36, 37 This lipid protective effect can be reversed by addition of the NOS inhibitors N G -aminohomoarginine 36 and N G -monomethylarginine. 37 When exogenous ⅐ NO is added to unstimulated macrophages, oxidation of LDL is inhibited. 38 In addition to the inhibition of inflammatory cell-mediated LDL oxidation, ⅐ NO will also inhibit LDL oxidation mediated by rabbit aortic endothelial cells. 39 Thus, ⅐ NO, derived from either ⅐ NO donors or iNOS, is able to protect LDL lipid from oxidation induced by Cu 2ϩ , macrophages, and endothelial cells, thereby potentially limiting atherogenesis. Ϫ /HOClmediated oxidation. 40, 41 These ⅐ NO-specific structural modifications can change the way oxidized LDL (oxLDL) interacts with endothelial cells and macrophages (Table 2) . Endothelial cells are protected from oxLDL toxicity in the presence of ⅐ NO donors. 42 However, the proatherogenic interaction of macrophages and LDL seems to be amplified when oxidant metabolites of ⅐ NO mediate LDL oxidation. Low density lipoprotein exposed to reactive nitrogen species (NO 2 -LDL) stimulates macrophage uptake through a specific receptor site 41, 43 that is neither the LDL receptor nor the scavenger receptor class A type I. 41 Macrophage uptake of NO 2 -LDL promotes cholesteryl ester synthesis, intracellular cholesterol and cholesteryl ester accumulation, and foam cell formation. 40, 41 Although ⅐ NO can inhibit LDL modification by terminating chain-propagating lipid oxidation reactions, the oxidant-stimulated formation of secondary lipid and protein structures by oxidant metabolites of ⅐ NO promotes the proatherogenic uptake of LDL by macrophages.
Reactive Nitrogen Species Alter the

⅐ NO Influences Formation of Bioactive Enzymatic Lipid Oxidation Products
Reactive nitrogen species can modulate the activity of lipidoxidizing enzymes such as cytochrome P450 4A, 44 12-and 15-LOX, and prostaglandin (PG) endoperoxide synthase (PGHS, or cyclooxygenase). These enzymes metabolize unsaturated fatty acids to bioreactive products, such as prostaglandins, leukotrienes, and thromboxanes. ONOO Ϫ can also oxidize arachidonic acid to bioactive F 2 -isoprostanes in liposomes and LDL. 45, 46 All of these products can modulate inflammatory reactions and vascular function (Table 3) .
PGHS-Mediated Metabolism of Arachidonic Acid Is Modulated by Reactive Nitrogen Species
PGHS catalyzes the initial step in prostaglandin formation, the oxidation of arachidonic acid to PGH 2 . Once formed, PGH 2 is converted by other enzymes to prostaglandins and thromboxane (TX; Table 3, Figure 1 ). PGHS has 2 active sites, a cyclooxygenase and a peroxidase site. Although the sites are separate, there is a heme prosthetic group between these catalytic centers that is required for both activities. The cyclooxygenase site incorporates 2 molecules of dioxygen into arachidonic acid to form the hydroper- ) and then form a tyrosyl radical on Tyr385 via intramolecular electron transfer. It is this tyrosyl radical intermediate that abstracts an hydrogen from arachidonic acid, forming a lipid radical that will react with oxygen. The heme prosthetic group is typically oxidized by peroxides. There are 2 isoforms of PGHS: constitutive (PGHS-1) and inducible (PGHS-2). The activities of both PGHS isoforms can be modulated by ⅐ NO and ONOO Ϫ , acting at different sites in the enzyme and its catalytic cycle.
Reactive Nitrogen Species Stimulate Synthesis of PGHS Metabolites In Vivo and in Cultured Cells
Although alkyl hydroperoxides have been viewed as the preferred substrate for oxidizing and "activating" the heme prosthetic group of PGHS, 47 ONOO Ϫ also readily serves as the oxidizing substrate. In fact, ONOO Ϫ stimulates PGHS cyclooxygenase activity even in the presence of hydroperoxide-scavenging reaction systems, such as glutathioneϩGPx, 47, 48 resulting in the proposal that ONOO Ϫ is a central mediator in tissue PGHS activation mechanisms.
For example, the concerted production of ⅐ NO and O 2 ⅐Ϫ stimulates PGHS activity in RAW264.7 cells, 49 supporting the concept that in systems in which ⅐ NO stimulates the synthesis of PGHS metabolites (Table 4) , ⅐ NO is actually acting as a precursor for ONOO Ϫ -mediated PGHS activation.
Reactive Nitrogen Species Inhibit Synthesis of PGHS Metabolites In Vivo and in Cultured Cells
Although inhibition of PGHS activity by ⅐ NO (Table 5) is observed in some cell culture systems, ⅐ NO does not inhibit purified enzyme. In the presence of arachidonate, ⅐ NO can cause nitrotyrosine formation at the catalytic Tyr385 of PGHS. However, this occurs only with concentrations of ⅐ NO that are too high to be biologically relevant. 61 Although ONOO Ϫ is capable of activating PGHS catalytic activity, it can indirectly decrease the net accumulation of PGHS metabolites. For example, on stimulation of ONOO Ϫ generation by rat mesangial cells, there is a concomitant decrease in cellular levels of PGH 2 -derived 6-keto-PGF 1␣ . ⅐ NO does not inhibit PGI 2 synthesis from PGH 2 , thereby supporting ONOO Ϫ as the inhibitor of PGI 2 synthase via nitration of critical tyrosine residues. 62 Although reactive nitrogen species can inhibit the net accumulation of PGHS metabolites in cell culture, this is most likely not attributed to the direct inhibition of PGHS.
Experimental Design Affects Reactive Nitrogen Species-Dependent Mediation of PGHS
There are several explanations for the opposing effects of reactive nitrogen species on PGHS activity. These can include differences in experimental design and ⅐ NO delivery rates that, in turn, influence the spectrum of ⅐ NO metabolites being formed. For instance, a ⅐ NO donor may be used to deliver ⅐ NO to the reaction system, but if O 2 ⅐Ϫ is being produced in the cell culture, ONOO Ϫ formation could occur and change the experimental outcome. Additionally, caution must be exercised when the markers for PGHS activity are based on tissue accumulation of downstream PGH 2 metabolites, such as PGE 2 , prostacyclin (PGI 2 , including 6-keto-PGF 1␣ , a stable PGI 2 metabolite), and TXB 2 . Downstream metabolism of PGH 2 can introduce additional opportunities for the modulation of other eicosanoid-metabolizing enzymes by reactive nitrogen species. ONOO Ϫ inhibition of PGI 2 synthase, an enzyme downstream from PGHS, underscores the complications that can arise from monitoring the extent of formation of only 1 or 2 metabolites and, from this, drawing a global conclusion about the regulation of PGHS. 62 In summary, multiple biologically relevant mechanisms may underlie the differing influences of reactive nitrogen species on PGHS activity.
⅐ NO Reaction With LOX
Lipoxygenases are a family of ubiquitously expressed nonheme iron-containing enzymes that oxidize the unsaturated fatty acids arachidonate and linoleate to bioactive hydroperoxides and secondary leukotriene products, thereby increasing atherogenic lipid oxidation. [63] [64] [65] [66] Activation of the catalytic iron of LOX involves peroxide-mediated oxidation from the Fe ϩ2 (E red ) to the Fe ϩ3 (E ox ) state. On lipid substrate binding to the active site, oxygen is stereospecifically inserted to form a lipid hydroperoxide (LOOH) that then dissociates, leaving E ox to reinitiate the catalytic cycle (Figure 2) .
Both pure enzyme-based and cell-based studies reveal that ⅐ NO consistently serves to inhibit LOX. In vitro, ⅐ NO reversibly inhibits soybean LOX type I co-oxidation of ␤-carotene in the presence of linoleate. 29 The ⅐ NO donor NOC7 inhibits rabbit platelet 12-LOX production of 12-hydroxy-5,8,10,14-eicosatetraenoic acid. However, in the presence of O 2 ⅐Ϫ , ⅐ NO is a less effective inhibitor of platelet 12-LOX, presumably because of the formation of ONOO Ϫ , a weak 12-LOX inhibitor. 60 Recent studies of mechanisms of ⅐ NO-mediated LOX inhibition show that formation of 13(S)-hydroperoxyoctadecadienoic acid by soybean and rabbit reticulocyte 15-LOX is reversibly inhibited by ⅐ NO (Figure 2 67 ) . Two distinct sites of interaction are observed between 15-LOX and physiological concentrations of ⅐ NO (1 to 6 mol/L). First, on peroxide activation of 15-LOX, ⅐ NO is consumed (2 mol ⅐ NO per 1 mol 15-LOX). Second, during dioxygenase turnover, ⅐ NO reacts with E red LOO ⅐ most likely to form an organic peroxynitrite (LOONO) that decomposes to LOOH and NO 2 Ϫ . The consumption of ⅐ NO by E red LOO ⅐ partially inhibits 15-LOX by leaving the enzyme in the inactive reduced state that must be activated again before continuing its catalytic cycle. 67 At higher, nonbiological ⅐ NO concentrations, an inactive ferrous nitrosyl complex can also form (E-Fe 2ϩ -NO) with E red . 67, 68 The concomitant consumption of ⅐ NO by 15-LOX may be of pathophysiological relevance, because ⅐ NO-dependent activation of sGC and the formation of cGMP are also impaired. 67 Thus, it can be inferred that when ⅐ NO is consumed ⅐Ϫ -rich milieu, ⅐ NO tends to limit lipid oxidation processes via reaction with lipid peroxyl radicals, 18 nitrosation of redox-active metalloproteins, 28 modulation of eicosanoid metabolism, 67 and deterring vascular wall infiltration of macrophages. 69 -72 Several studies using cholesterol-fed rabbits have demonstrated that ⅐ NO inhibits and may even reverse the progression of atherogenesis. For example, administration of the NOS inhibitor N G -nitro-L-arginine methyl ester leads to significant increases in atherosclerotic lesion formation. 73 Also, L-arginine supplementation results in improved vascular relaxation and a decrease in vascular lesion surface area. Interestingly, rates of vascular ⅐ NO production are seen to increase, whereas O 2 ⅐Ϫ generation decreases. 74 ⅐ NO produced in vivo by iNOS also protects rat aorta from the development of allograft arteriosclerosis. 75 In a rat carotid artery ballooninjury model, endothelial NOS gene transfection restores ⅐ NO production to preinjury levels and inhibits neointimal hyperplasia, further demonstrating the vascular protective effects of ⅐ NO. 76 In opposition to the antiatherogenic properties of ⅐ NO displayed in animal models; secondary products of ⅐ NO oxidation, NO 2 Ϫ and ⅐ NO 2 , lead to proatherogenic LDL modification that promotes the accumulation of intracellular cholesterol and cholesteryl esters along with foam cell formation. 41 The contrast between atherogenic properties of ⅐ NO and its oxidant metabolites underscores the difference in function of ⅐ NO production in locations of high oxidant stress versus lower oxidant stress. As long as the concentration of ⅐ NO is higher than that of surrounding oxidants, ⅐ NO is able to maintain a protective role in the vasculature.
⅐ NO Inhibits Proinflammatory Genes
One mechanism underlying the antiatherogenic actions of ⅐ NO is indirect inhibition of lipid oxidation reactions by ⅐ NO-dependent modulation of cell signal transduction mechanisms. During an inflammatory response, ⅐ NO can inhibit the activation of the transcription factor nuclear factor-B (NF-B) by inducing expression of the NF-B inhibitor, IB␣, and stabilizing the NF-B/IB␣ complex. 69 NF-B inhibition causes downregulation of the expression of several proinflammatory genes that promote interstitial migration of monocytes and neutrophils, as well as monocyte differentiation within the vascular compartment. For example, ⅐ NO inhibits endothelial and smooth muscle cell expression of adhesion molecules via NF-B during inflammatory reactions, specifically the expression of intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1 (E-selectin). 70 -72 Without adhesion molecule expression, there is a decrease in the ability of monocytes and neutrophils to migrate into the vascular wall. Thus, macrophage accumulation in the arterial intima and the subsequent oxidation of LDL is reduced. NF-B is also a transcription factor for the cytokines interleukin-6 and interleukin-8 69 and macrophage colonystimulating factor (M-CSF), 77 all participating in the regulation of macrophage growth and differentiation. In aortic lesions of rabbits on high cholesterol diets, M-CSF is found to be elevated 2-fold. 77 Because M-CSF expression is stimulated by oxLDL, ⅐ NO attenuation of LDL oxidation may thus indirectly limit the expression of M-CSF. Although the antiatherogenic roles of ⅐ NO may shift in the extent and mechanism(s) of action as the disease progresses, ⅐ NO appears to initially attenuate macrophage-mediated lipid oxidation by limiting the presence of monocytes within the vascular compartment, thereby possibly also directly inhibiting proatherogenic oxidative reactions. Thus, by inhibiting NF-B activation, ⅐ NO exploits the cascading properties of signaling pathways to protect the vascular compartment from monocyte-induced lipoprotein oxidation.
Conclusion
There is rapidly evolving insight into the modulation of nonenzymatic and enzymatic lipid oxidation reactions by ⅐ NO, revealing important new non-cGMP-dependent reactivities for this free radical inflammatory and signal transduction mediator. Chemically, ⅐ NO reacts Ϸ10 4 -fold faster than does ␣-TH with lipid peroxyl radicals, suggesting that novel antioxidant properties exist for ⅐ NO. Indeed, with respect to the inhibition of lipid oxidation, ⅐ NO and ␣-TH are better cooperative antioxidant partners than are ascorbic acid and ␣-TH. ⅐ NO is also a potent modulator of LOX and PGHS activities; this enzyme interaction profoundly affects the rate of eicosanoid production, local steady-state concentrations of ⅐ NO, and cGMP-dependent signaling reactions mediated by ⅐ NO. Finally, ⅐ NO will inhibit proinflammatory platelet aggregation, integrin gene expression, and vessel wall inflammatory cell margination, all leading to a general attenuation of vascular inflammation and oxidative injury.
In the presence of O 2 ⅐Ϫ or peroxidases, ⅐ NO and its oxidation product NO 2 Ϫ can display pathogenic properties on conversion to the reactive oxidizing species ONOO Ϫ , ⅐ NO 2 , and NO 2 Cl. These species can oxidize and nitrate target molecules, thus generating products with altered structurefunction characteristics. In the context of LDL modification, the ⅐ NO-mediated oxidation and nitration of lipid and protein components of LDL are highly proatherogenic because of enhanced macrophage uptake.
The most crucial determinant of the opposing tissueprotective versus proinflammatory manifestations of ⅐ NO reactivity is the underlying oxidative stress of tissues, in particular, the occurrence of accelerated rates of O 2 ⅐Ϫ and H 2 O 2 production, impaired oxidant defenses, and increased peroxidase content. This precept then presents a challenge for the future-the need to develop potent vessel-targeted scavengers of reactive oxygen species so that the salutary actions of ⅐ NO toward signaling events and lipid oxidation
